FIGURE 4.

Transplant-free survival^a up to 90 days using cumulative incidence function with competing risks of transplant and death by baseline serum creatinine subgroup (terlipressin group, pooled ITT population^b). ^aA Fine and Gray proportional hazards model was used to produce cumulative incidence function estimates of transplant-free survival, with transplant as a competing risk for death. ^bPooled data were collated from the following Phase III studies: OT-0401, REVERSE, and CONFIRM. ITT indicates intent-to-treat.